MegaPro Biomedical Co

MegaPro Biomedical Co EBITDA

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of MegaPro Biomedical Co (6827.TWO) as of Nov 18, 2026 is -119.59 M TWD. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was -180.19 M TWD — a change of -33.63% (higher).

EBITDA

-119.59 MTWD

YoY

-33.63%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of MegaPro Biomedical Co is 2025 -119.59 M TWD. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of MegaPro Biomedical Co was 2024 -180.19 M TWD. It decreases by -33.63% higher compared to the previous year.

The MegaPro Biomedical Co EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA
Date
EBITDA
Jan 1, 2018
-160.77 M TWD
Jan 1, 2019
-178.34 M TWD
Jan 1, 2020
-149.33 M TWD
Jan 1, 2021
-100.98 M TWD
Jan 1, 2022
-121.75 M TWD
Jan 1, 2023
-140.49 M TWD
Jan 1, 2024
-180.19 M TWD
Jan 1, 2025
-119.59 M TWD
The MegaPro Biomedical Co EBITDA history
YEAREBITDAYoY
-119.59 MTWD-33.63%
-180.19 MTWD+28.26%
-140.49 MTWD+15.39%
-121.75 MTWD+20.57%
-100.98 MTWD-32.38%
-149.33 MTWD-16.27%
-178.34 MTWD+10.93%
-160.77 MTWD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

MegaPro Biomedical Co Stock analysis

What does MegaPro Biomedical Co do? MegaPro Biomedical Co., Ltd. generates revenue through its development of drug ingredients utilizing nanoparticle and nanocell technology platforms. The company's primary products are MPB-1514, MPB-1523, MPB-1734, and MPB-2043, each targeting specific medical conditions. MPB-1514 treats anemia in chronic kidney disease patients via intravenous injection, while MPB-1523 diagnoses hepatocellular carcinoma through intravenous administration. MPB-1734 addresses solid tumors with intravenous treatment, and MPB-2043 aids in diagnosing metastases in peripheral lymph nodes of cancer sites. These products are sold to healthcare providers and medical institutions requiring advanced diagnostic and therapeutic solutions. The company focuses on two core technology platforms: nanoparticle and nanocell, which underpin its product development. Its product portfolio targets chronic kidney disease, hepatocellular carcinoma, solid tumors, and cancer metastasis diagnostics. These applications are directed toward medical professionals and facilities specializing in oncology and nephrology. The firm's revenue model relies on the commercialization of these specialized drug ingredients for targeted medical treatments and diagnostics. MegaPro Biomedical's products are designed for intravenous use across various medical conditions, positioning the company within the biotechnology sector. Its revenue streams come from the sale of these proprietary drug ingredients to hospitals, clinics, and research institutions. The company's market segments include healthcare providers treating kidney disease, cancer diagnostics, and oncology-focused medical facilities seeking innovative therapeutic solutions. MegaPro Biomedical Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about MegaPro Biomedical Co stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of MegaPro Biomedical Co is -119.59 M TWD in 2025.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of MegaPro Biomedical Co changed from -180.19 M TWD to -119.59 M TWD, representing a -33.63% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) MegaPro Biomedical Co since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s TWD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s MegaPro Biomedical Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — MegaPro Biomedical Co

All Key Metrics — MegaPro Biomedical Co